Human Papillomavirus and Epstein Barr Virus in Head and Neck Carcinomas: Suggestions for the New WHO Classification

被引：28
作者：
Lewis Jr. J.S. [1 ,2 ]
Chernock R.D. [1 ,2 ]
机构：
[1] Division of Anatomic and Molecular Pathology, Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, 63110, Campus Box 8118
[2] Department of Otolaryngology Head and Neck Surgery, Washington University School of Medicine, St. Louis, MO, 63110, Campus Box 8118
来源：
Head and Neck Pathology | 2014年 / 8卷 / 1期
关键词：
Classification; Epstein-Barr virus; Human papillomavirus; p16; Squamous cell carcinoma; World Health Organization;
D O I：
10.1007/s12105-014-0528-6
中图分类号：
学科分类号：
摘要：
In the 9 years since the last World Health Organization (WHO) classification for head and neck tumors, a great deal has changed. In particular, human papillomavirus (HPV) has emerged as the major etiologic agent and patient prognostic marker for squamous cell carcinoma, most profoundly in the oropharynx. It also casts a long shadow over all of the rest of head and neck cancer given its biologic and prognostic implications. By contrast, little has changed regarding our knowledge of Epstein-Barr virus in head and neck cancers, except as it relates to HPV in nonkeratinizing-type nasopharyngeal carcinomas. This article discusses some of the major advances in our understanding of virus-related squamous cell carcinoma of the head and neck and suggests several specific concepts and terminology for incorporation into the next WHO classification. © 2014 Springer Science+Business Media New York.
引用
收藏
页码：50 / 58
页数：8
相关论文
共 30 条
  • [1] Johnson N., Francheschi S., Ferlay J., Et al., Squamous cell carcinoma of the oral cavity and oropharynx, World Health Organization Classification of Tumours-Pathology and Genetics Head and Neck Tumours, pp. 168-175, (2005)
  • [2] Wu X., Watson M., Wilson R., Et al., Human papillomavirus-associated cancers-United States, 2004-2008, Morb Mortal Wkly Rep, 61, 15, pp. 258-261, (2012)
  • [3] Ang K.K., Harris J., Wheeler R., Et al., Human papillomavirus and survival of patients with oropharyngeal cancer, N Engl J Med, 363, 1, pp. 24-35, (2010)
  • [4] Chaturvedi A.K., Engels E.A., Pfeiffer R.M., Et al., Human papillomavirus and rising oropharyngeal cancer incidence in the United States, J Clin Oncol, 29, 32, pp. 4294-4301, (2011)
  • [5] Ang K.K., Sturgis E.M., Human papillomavirus as a marker of the natural history and response to therapy of head and neck squamous cell carcinoma, Semin Radiat Oncol, 22, 2, pp. 128-142, (2012)
  • [6] Jordan R.C., Lingen M.W., Perez-Ordonez B., Et al., Validation of methods for oropharyngeal cancer HPV status determination in US cooperative group trials, Am J Surg Pathol, 36, 7, pp. 945-954, (2012)
  • [7] Ukpo O.C., Flanagan J.J., Ma X.J., Et al., High risk human papillomavirus E6/E7 mRNA detection by a novel in situ hybridization assay strongly correlates with p16 expression and patient outcomes in oropharyngeal squamous cell carcinoma, Am J Surg Pathol, 35, 9, pp. 1343-1350, (2011)
  • [8] Robinson M., Schache A., Sloan P., Et al., HPV specific testing: a requirement for oropharyngeal squamous cell carcinoma patients, Head Neck Pathol, 6, SUPPL. 1, (2012)
  • [9] Robinson M., Sloan P., Shaw R., Refining the diagnosis of oropharyngeal squamous cell carcinoma using human papillomavirus testing, Oral Oncol, 46, 7, pp. 492-496, (2010)
  • [10] Lewis Jr. J.S., p16 immunohistochemistry as a standalone test for risk stratification in oropharyngeal squamous cell carcinoma, Head Neck Pathol, 6, SUPPL. 1, pp. 75-82, (2012)
123